Mo, Hongnan
Huang, Jing
Xu, Jiachen
Chen, Xuelian
Wu, Dawei
Qu, Dong
Wang, Xi
Lan, Bo
Wang, Xingyuan
Xu, Jianping
Zhang, Honggang
Chi, Yihebali
Yang, Qing
Xu, Binghe
Article History
Received: 5 January 2018
Revised: 5 April 2018
Accepted: 10 April 2018
First Online: 14 May 2018
Competing interests
: Q.Y. is a salaried employee of Jiangsu Hengrui Medicine Co. The remaining authors declare no competing interests.
: The datasets generated during and/or analysed during the current study are available from the corresponding authors on reasonable request.
: This clinical trial was approved by the Institutional review board and independent ethics committee of National Cancer Center, Cancer Hospital, Chinese Academy of Medical Sciences. It was conducted in accordance with the Declaration of Helsinki and the international standards of good clinical practice. Informed consents had been obtained from all patients in the study.
: This study was funded by the Jiangsu Hengrui Medicine Co. Ltd, who provided the study drug. This study was partially supported by the National Key Basic Research Program of China (973 program no. 2015CB553902). This study was supported by grant from CAMS Initiative for Innovative Medicine (CAMS-12M-1-010).
: This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).